CLINICAL EXPERIENCE WITH FIRST-LINE VRD IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA

被引：0
|
作者：
De Miguel, Llorente Dunia [1 ]
Gil, Perez Angela [1 ]
Merchan, Munoz Beatriz [1 ]
Nuevo, Lopez Irene [1 ]
Perez, Ortega Alba [1 ]
Guillen, Garcia Helga [1 ]
Vazquez, Ramo Alejandro [1 ]
Subira, Perez Dolores [1 ]
Golbano, Lopez Nuria [1 ]
Santos, Montero Ana Belen [1 ]
Morales, Sanz Dolores [1 ]
Arbeteta, Juanis Jaime [1 ]
机构：
[1] Hosp Univ Guadalajara, Guadalajara, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-026
引用
收藏
页码：150 / 151
页数：2
相关论文
共 50 条
  • [21] Trials investigate first-line thalidomide in multiple myeloma
    Owen, OG
    LANCET ONCOLOGY, 2005, 6 (01): : 6 - 6
  • [22] A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma
    Jagannath, S
    Brian, D
    Wolf, JL
    Camacho, E
    Irwin, D
    Lutzky, J
    McKinley, M
    Gabayan, E
    Mazumder, A
    Crowley, J
    Schenkein, D
    BLOOD, 2004, 104 (11) : 98A - 99A
  • [23] ASH 2021 Isatuximab supplements First-line Therapy in Patients with Multiple Myeloma
    Habel, Christoph
    ACTA HAEMATOLOGICA, 2022, 145 (02) : 232 - 232
  • [24] Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients
    Ran, Tao
    Medhekar, Rohan
    Fu, Alex Z.
    Patel, Sharmila
    Kaila, Shuchita
    FUTURE ONCOLOGY, 2022, 18 (36) : 3983 - 3991
  • [25] Outcomes with Early Response to First Line Treatment in Patients with Newly Diagnosed Multiple Myeloma
    Tandon, Nidhi
    Sidana, Surbhi
    Rajkumar, S. Vincent
    Kapoor, Prashant
    Gonsalves, Wilson I.
    Dispenzieri, Angela
    Gertz, Morie A.
    Kourelis, Taxiarchis
    Warsame, Rahma
    Buadi, Francis K.
    Lacy, Martha Q.
    Dingli, David
    Fonder, Amie
    Hayman, Suzanne R.
    Hobbs, Miriam
    Hwa, Yi L.
    Kyle, Robert A.
    Leung, Nelson
    Go, Ronald S.
    Lust, John A.
    Russell, Stephen J.
    Kumar, Shaji K.
    BLOOD, 2017, 130
  • [26] First-line Treatment for Patients with Multiple Myeloma (vol 60, pg 23, 2018)
    Breitkreutz, I.
    Raab, M.
    Goldschmidt, H.
    INTERNIST, 2019, 60 (05): : 552 - 552
  • [27] Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma
    Zou, Yandun
    Sheng, Zhixin
    Niu, Shaona
    Wang, Huijuan
    Yu, Jinming
    Xu, Jingbo
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2219 - 2225
  • [28] LIPID AND LIPOPROTEIN PROFILE OF PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER FIRST-LINE TREATMENT
    Hatziri, A.
    Lazaris, V.
    Symeonidis, A.
    Kypreos, K. E.
    ATHEROSCLEROSIS, 2021, 331 : E125 - E125
  • [29] Experience at Son Espases University Hospital with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd) as first line treatment in multiple myeloma
    Monsonis, Lola Piquer
    Sampalo, Maria Gali
    Montana, Albert Perez
    Raga, Jose Maria Sanchez
    Mayol, Antonia Sampol
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S122 - S122
  • [30] RD Vs. VRD: What Is the First-Line, Real-Life Management of Multiple Myeloma Patients Ineligible for Stem Cell Auto Transplantation in the Emmy Cohort?
    Decaux, O.
    Perrot, A.
    Frenzel, L.
    Royer, B.
    Araujo, C.
    Belhadj, K.
    Moreau, P.
    Caillot, D.
    Leleu, X.
    Farge, A.
    Vekhoff, A.
    Schulmann, S.
    Fontan, J.
    Orsini, Frederique
    Sanhes, L.
    Richez, V.
    Jaccard, A.
    Garlantezec, R.
    Texier, N.
    Germain, R.
    Boccaccio, C.
    Hulin, C.
    BLOOD, 2021, 138 : 3766 - +
12345